At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection ...
Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine ...
Q. I would encourage anyone on the fence about getting the Shingrix vaccine to seriously consider it. My elderly father had the older shingles vaccine but not Shingrix. Several years ago, he had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results